Total Liabilities (Quarterly)

Total Liabilities: The total value of all possible claims against the corporation.

ImmuCell Corporation (ICCC) had Total Liabilities of $16.63M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$8.07M
Net Income	$1.45M
Cost of Goods Sold	$4.71M
Gross Profit	$3.35M
Operating Expenses	$6.95M
Operating Income	$1.12M
Non-Operating Income/Expense	$0.33M
Pre-Tax Income	$1.45M
Normalized Pre-Tax Income	$1.45M
Income after Taxes	$1.45M
Income from Continuous Operations	$1.45M
Consolidated Net Income/Loss	$1.45M
Normalized Income after Taxes	$1.45M
EBIT	$1.12M
EBITDA	$1.80M
Weighted-Average Shares Outstanding (Basic)	8.98M
Weighted-Average Shares Outstanding (Diluted)	8.98M
Earnings per Share (EPS) (Basic)	$0.16
Earnings per Share (EPS) (Diluted)	$0.16
Balance Sheet Financials
Current Assets	$15.92M
Property, Plant, and Equipment	$25.02M
Long-Term Assets	$29.70M
Total Assets	$45.62M
Current Liabilities	$3.87M
Long-Term Debt	$8.65M
Long-Term Liabilities	$12.76M
Total Liabilities	$16.63M
Common Equity	$28.99M
Tangible Shareholders Equity	$28.88M
Shareholders Equity	$28.99M
Common Shares Outstanding	8.98M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.57M
Cash Flow from Investing Activities	$-0.33M
Cash Flow from Financial Activities	$-0.40M
Beginning Cash	$3.76M
End Cash	$4.60M
Increase/Decrease in Cash	$0.84M
Stock-Based Compensation	$0.05M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.12
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.23
Debt to Equity Ratio	0.35
Gross Margin	41.58%
Operating Margin	13.85%
EBIT Margin	13.85%
EBITDA Margin	--
Pre-Tax Profit Margin	17.96%
Profit Margin	17.94%
Free Cash Flow	$1.24M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.18
Inventory Turnover	0.64
Receiveable Turnover	2.41
Days Sales in Receivables	37.33
Return on Equity	4.99%
Return on Tangible Equity	5.01%
Return on Assets	3.17%
Return on Investments	3.84%
Book Value Per Share	$3.23
Free Cash Flow per Share	$0.14
Operating Cash Flow per Share	$0.18

Data from Zacks Investment Research, Inc.